Australia's most trusted
source of pharma news
Wednesday, 22 January 2025
Posted 16 January 2025 AM
Sandoz is closing in on Amgen's $303 million Prolia and Xgeva franchise, revealing that its biosimilars will be added to the PBS on 1 August.
Amgen's products utilise the same active denosumab however, Prolia is indicated for certain types of osteoporosis while Xgeva is indicated for cancer-related bone disease.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.